H. Jang

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
H Jang, H. Jang, Haishan Jang
Publication record
17 papers · 492 citations · H-index 7

PAPERS

Preclinical safety, pharmacokinetics, pharmacodynamics and biodistribution studies with Ad35K++ protein, a novel rituximab co‐therapeutic in mice and non‐human primates.
20160 citationsauthor #9
Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic
201616 citationsauthor #10
[Expression of monocarboxylate transporter 8 mRNA in the brain tissue of rats with cerebral ischemia].
20122 citationsauthor #3
Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimetibody™ Construct CNTO 528 in Healthy Subjects
200936 citationsauthor #5
A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects
200842 citationsauthor #11
Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis
2007191 citationsauthor #2
Pharmacokinetics and Pharmacodynamics of CNTO 528, a Novel Erythropoietin Receptor Agonist in Normal and Anemic Rats.
20055 citationsauthor #12
A Phase I, Single and Fractionated, Ascending Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietic Mimetic Antibody Fusion Protein, CNTO528, in Healthy Male Subjects.
20053 citationsauthor #6
Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-αv Integrin Monoclonal Antibody, Despite Widespread Tissue Binding
200540 citationsauthor #9
Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys
2005130 citationsauthor #6
Correlation of serum CNTO 328-Anti IL-6 monoclonal antibody (MAb) concentrations and biomarker expression in renal cell carcinoma (RCC) patients.
20041 citationsauthor #2
A rational approach for a phase I clinical study design to evaluate CNTO 95, a novel, fully human anti-avmonoclonal antibody (MAb), in patients with solid tumors.
20043 citationsauthor #3
Pharmacokinetics and pharmacodynamics of a human anti‐TNF‐alpha monoclonal antibody in patients with rheumatoid arthritis
20040 citationsauthor #1
Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors.
200421 citationsauthor #7
Pharmacokinetic/pharmacodynamic (PK/PD) modeling and trial simulations to guide dose selection with CNTO 328, a chimeric anti-IL-6 monoclonal antibody (MAb), in patients with renal cell carcinoma (RCC).
20041 citationsauthor #1
PK modeling and simulations of an anti IL‐6 MAB in patients with renal cell carcinoma
20040 citationsauthor #2
Correlation of serum CNTO 328-Anti IL-6 monoclonal antibody (MAb) concentrations and biomarker expression in renal cell carcinoma (RCC) patients
20040 citationsauthor #2

TIMELINE

2004 26 citations

2005 178 citations

2007 191 citations

2008 42 citations

2009 36 citations

2012 2 citations

2016 16 citations

H. Jang

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT